As a clinician-scientist, Professor Dawson has consistently demonstrated academic excellence and leadership both in basic science discoveries and the translation of these findings into the clinical arena. His research into chromatin regulation of normal and malignant haematopoiesis have provided a range of groundbreaking discoveries including the development in collaboration with GSK of the first clinical therapies that target epigenetic reader proteins. This body of work helped establish a new therapeutic paradigm for the treatment of aggressive malignancies. Importantly, he continues to translate these discoveries by leading the multinational clinical trials that have been initiated as a direct consequence of his research.